Changing patterns of referral into a family history clinic and detection of ovarian cancer: a retrospective 10-year review

References

• Andriole GL, Crawford ED, Grubb RL 3rd., Buys SS, Chia D, Church TR, et al. 2012. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. Journal of the National Cancer Institute 104:125–132.
   PubMed Web of Science ®Google Scholar
• Barclay M, Gildea C, Poole J, Hirschowitz L, Menon U, Nordin A. 2016. Factors affecting short-term mortality in women with ovarian, tubal, or primary peritoneal cancer: population-based cohort analysis of English National Cancer registration data. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 26:56–65.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:7353 609–15.
   Web of Science ®Google Scholar
• Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. 2005. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecologic Oncology 97:457–467.
   PubMed Web of Science ®Google Scholar
• Chandrasekaran D, Menon U, Evans G, Crawford R, Saridogan E, Jacobs C, et al. 2015. Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. Familial Cancer 14:521–530.
   PubMed Web of Science ®Google Scholar
• Crispens MA. 2012. Endometrial and ovarian cancer in lynch syndrome. Clinics in Colon and Rectal Surgery 25:97–102.
   PubMedGoogle Scholar
• Crosbie EJ, Flaum N, Harkness EF, Clayton RD, Holland C, Martin-Hirsch P, et al. 2021. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels. International Journal of Cancer 148:1155–1163.
   PubMed Web of Science ®Google Scholar
• de Jonge MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, van Wezel T, van Aspere CJ, et al. 2017. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: a meta-analysis and case report. European Journal of Cancer (Oxford, England: 1990) 72:215–225.
   PubMed Web of Science ®Google Scholar
• Dowdy SC, Stefanek M, Hartmann LC. 2004. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. American Journal of Obstetrics and Gynecology 191:1113–1123.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff E, Eeles R, et al. 2010. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Research and Treatment 124:195–203.
   PubMed Web of Science ®Google Scholar
• Easton DF, Ford D, Bishop DT. 1995. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. American Journal of Human Genetics 56:265–271.
   PubMed Web of Science ®Google Scholar
• Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO. 2018. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database of Systematic Reviews 8:CD012464.
   PubMedGoogle Scholar
• Evans DGR, Lalloo F, Wallace A, Rahman N. 2005. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. Journal of Medical Genetics 42:e39.
   PubMed Web of Science ®Google Scholar
• Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER. 2008. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting. BMC Cancer 8:155.
   PubMed Web of Science ®Google Scholar
• Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. 2006. Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296:185–192. 12;
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. 1998. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. The American Journal of Human Genetics 62:676–689.
   PubMed Web of Science ®Google Scholar
• Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. 2015. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genetics in Medicine : Official Journal of the American College of Medical Genetics 17:70–87.
   PubMed Web of Science ®Google Scholar
• Harmsen MG, Arts-de Jong M, Hoogerbrugge N, Maas AH, Prins JB, Bulten J, et al. 2015. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer 15:593.
   PubMed Web of Science ®Google Scholar
• Iavazzo C, Gkegkes ID, Vrachnis N. 2016. Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy. Journal of the Turkish German Gynecological Association 17:73–76.
   PubMedGoogle Scholar
• Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. 2002. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. The New England Journal of Medicine 346:1609–1615.
   PubMed Web of Science ®Google Scholar
• Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. 2017. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317:2402–2416. longtermplan.nhs.uk
   PubMed Web of Science ®Google Scholar
• Manchana T, Phoolcharoen N, Tantbirojn P. 2019. BRCA mutation in high grade epithelial ovarian cancers. Gynecologic Oncology Reports 29:102–105.
   PubMed Web of Science ®Google Scholar
• Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, et al. 2014. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all-cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 14:150.
   PubMed Web of Science ®Google Scholar
• Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. 2006. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. The American Journal of Surgical Pathology 30:230–236.
   PubMed Web of Science ®Google Scholar
• Meyer LA, Broaddus RR, Lu KH. 2009. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control : journal of the Moffitt Cancer Center 16:14–22.
   PubMed Web of Science ®Google Scholar
• National Institute of Clinical Excellence (NICE). 2006. Familial breast cancer. Clinical Guideline (CG41) (since updated). Available from: https://www.nice.org.uk/guidance/cg164/evidence/full-guideline-pdf-190130941
   Google Scholar
• National Institute of Clinical Excellence (NICE). 2013. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Clinical Guideline (CG164). Available from: https://www.nice.org.uk/guidance/cg164/evidence/full-guideline-pdf-190130941
   Google Scholar
• NHS England. (2018). National genomic test directories. Available from: www.england.nhs.uk/publication/national-genomic-test-directories
   Google Scholar
• Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, et al. 2015. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review. Gynecologic Oncology 139:568–572.
   PubMed Web of Science ®Google Scholar
• Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, et al. 2005. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23:127–132.
   PubMed Web of Science ®Google Scholar
• Prat J, Ribe A, Gallardo A. 2005. Hereditary ovarian cancer. Human Pathology 36:861–870.
   PubMed Web of Science ®Google Scholar
• Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. 2016. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncology 2:1434–1440.
   PubMed Web of Science ®Google Scholar
• Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, et al. 2014. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Human Molecular Genetics 23:4703–4709.
   PubMed Web of Science ®Google Scholar
• Steenbeek MP, Harmsen MG, Hoogerbrugge N, de Jong MA, Maas A, Prins JB, et al. 2021. Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1/2 pathogenic variant carriers: a nonrandomized controlled trial. JAMA Oncology 7:1203–1212.
   PubMed Web of Science ®Google Scholar
• Strong VE, Selby LV, Sovel M, Disa JJ, Hoskins W, Dematteo R, et al. 2015. Development and assessment of Memorial Sloan Kettering Cancer Center's Surgical Secondary Events grading system. Annals of Surgical Oncology 22:1061–1067.
   PubMed Web of Science ®Google Scholar
• The Health Policy Partnership. 2019. Available from: https://www.healthpolicypartnership.com/app/uploads/Genetic-testing-for-BRCA-mutations-Germany.pdf
   Google Scholar
• Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, et al. 2013. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 23:1603–1611.
   PubMed Web of Science ®Google Scholar
• Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, et al. 2016. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecologic Oncology 143:231–235.
   PubMed Web of Science ®Google Scholar